Skip to main content
. 2020 Mar 26;8:39. doi: 10.1186/s40478-020-00914-9

Table 2.

Demographics and clinical characteristics of donors with LP, PSP tau pathology, GCI pathology and other types of pathology

LP PSP tau pathology GCI pathology Other types of pathology
N 162 45 28 58
Sex M, n (%) 102 (63%) 28 (62%) 10 (36%)** 36 (62%)

Age at onset y, mean ± SD (range)

<  50 / 50–75 / >  75 y, n (%)

62 ± 11 (32–88)

26/117/19 (16/72/12%)

66 ± 7 (51–84)**

0/40/5 (0/89/11%)

59 ± 9 (45–81)

3/23/2 (11/82/7%)

64 ± 12 (34–84)

7/43/8 (12/74/14%)

Age at death y, mean ± SD (range) 77 ± 8 (56–96) 74 ± 8 (57–90) 66 ± 9 (52–84)*** 76 ± 11 (42–98)
Disease duration y, mean ± SD (range) 15 ± 7 (2–42) 8 ± 4 (3–23)*** 7 ± 3 (3–16)*** 11 ± 9 (0.5–41)**
Dementia, n (%) 89 (55%) 12 (27%)*** 2 (7%)*** 30 (52%)
Duration of dementia y, mean ± SD (range) 4 ± 3 (0–12) 2 ± 2 (0–6)** 1 ± 1 (0–1) 3 ± 2 (0–10)
Visual hallucinations, n/N (%) 93/122 (76%) 10/13 (77%) 5/7 (71%) 9/13 (69%)
Rest tremor, n/N (%) 112/134 (84%) 11/30 (37%)*** 16/24 (67%) 29/37 (78%)
Clear response to dopaminergic therapy, n/N (%) 106/126 (84%) 6/26 (23%)*** 11/24 (46%)*** 10/26 (39%)***
Positive family history of parkinsonism, n/N (%) 31/80 (39%) 7/28 (25%) 3/17 (18%) 8/29 (28%)
APOE ε4 alleles, n/N (%)
 0 67/101 (66%) 23/39 (59%) 12/23 (52%) 33/43 (77%)
 1 31/101 (31%) 15/39 (39%) 9/23 (39%) 9/43 (21%)
 2 3/101 (3%) 1/39 (3%) 2/23 (9%) 1/43 (2%)

Groups are compared using analysis of covariance for continuous variables and chi-square tests for categorical variables. When significant, the LP group was compared to the other pathology groups using post-hoc tests for continuous variable and chi-square tests for categorical variables.* p < 0.05; ** p < 0.01; *** p < 0.001